Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 19 of 221 for:    Recruiting, Not yet recruiting, Available Studies | Acute kidney injury

China Collaborative Study on Epidemiology of Acute Kidney Injury

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03054142
Recruitment Status : Recruiting
First Posted : February 15, 2017
Last Update Posted : January 7, 2019
Sponsor:
Information provided by (Responsible Party):
XinLing Liang, Guangdong General Hospital

Brief Summary:
Acute kidney injury (AKI) is a common clinical syndrome, especially patients in the hospital. AKI has become a huge medical burden in China. Little information is available about this disease burden in our country. The investigators aimed to evaluate the burden of AKI and to analyze the related risk factors.

Condition or disease Intervention/treatment
Acute Kidney Injury Other: no intervention

Detailed Description:
The investigators launch a nationwide of all patients, who were admitted to hospital from 2011-2016. Patients were diagnosed on the basis of changes in serum creatinine by the laboratory information system. The investigators assessed rates of AKI according to the criteria of 2012 Kidney Disease Improving Global Outcomes (KDIGO).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000000 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: China Collaborative Study on Epidemiology of Acute Kidney Injury
Study Start Date : January 2017
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Group/Cohort Intervention/treatment
AKI Other: no intervention
non-AKI Other: no intervention



Primary Outcome Measures :
  1. Incidence of AKI [ Time Frame: Jan. 2011 to Oct. 2016 ]

Secondary Outcome Measures :
  1. Recognition rate of AKI [ Time Frame: Jan. 2011 to Oct. 2016 ]
    Using machine learning and deep learning methods to establish AKI prediction model and risk models

  2. Proportion of nephrology referral [ Time Frame: Jan. 2011 to Oct. 2016 ]
  3. In-hospital mortality [ Time Frame: Jan. 2011 to Oct. 2016 ]
  4. Longer ICU stay [ Time Frame: Jan. 2011 to Oct. 2016 ]
  5. Higher medical cost [ Time Frame: Jan. 2011 to Oct. 2016 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
All inpatients (if outpatient identification is achieved, outpatient and inpatient patients can be judged to be the same individual, the outpatient electronic data is extracted at the same time)
Criteria

Inclusion Criteria:

  • The patients diagnosed on the basis of changes in serum creatinine according to the criteria of 2012 Kidney Disease Improving Global Outcomes(KDIGO)

Exclusion Criteria:

  • Serum creatinine record less than two times during hospitalization
  • Patients being diagnosed with End-stage kidney disease (chronic kidney disease stage 5)
  • Nephrectomy
  • Kidney transplantation
  • Peak serum creatinine of less than 53µ mol/L
  • Serum creatinine decrease after amputation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03054142


Contacts
Layout table for location contacts
Contact: Liang Xinling, M.D.,Ph.D 13808819770 xinlingliang@139.com
Contact: Liang Xinling, M.D.,Ph.D 86-13808819770 xinlingliang@139.com

Locations
Layout table for location information
China, Guangdong
Nephrology Dept,Guangdong General Hospital Recruiting
Guangzhou, Guangdong, China
Contact: Liang Xinling, MD,PhD    86-13808819770    xinlingliang@139.com   
Sponsors and Collaborators
XinLing Liang
Investigators
Layout table for investigator information
Principal Investigator: Liang Xinling, M.D.,Ph.D Nephrology Dept,Guangdong General Hospital

Layout table for additonal information
Responsible Party: XinLing Liang, Director of Division of Nephrology and Blood Purification Center of Guangdong General Hospital, Guangdong General Hospital
ClinicalTrials.gov Identifier: NCT03054142     History of Changes
Other Study ID Numbers: CCS-AKI RF2011-2016
First Posted: February 15, 2017    Key Record Dates
Last Update Posted: January 7, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases